Education

University of Delaware, Newark, Delaware, BS, 1985, Chemistry
University of North Carolina at Chapel Hill, PhD, 1990, Analytical Chemistry/ Materials Science
University of North Carolina School of Medicine, MD, 1992-1996, Medicine
University of California, San Francisco, CA Resident, 1996-00, Pathology/ Laboratory Medicine
Brigham and Womens Hospital and Harvard Medical School, Boston, MA, Clinical Fellow, 2000-01, Molecular Pathology
University of California, San Francisco, CA, Clinical Fellow, 2001-02, Surgical Pathology

Honors & Awards

  • 1984
    American Chemical Society, U. of Delaware Analytical Chemistry Award
  • 1994
    Howard Hughes Trust Fund Fellowship
  • 1994
    UNC School of Medicine Foreign Fellowship
  • 1994
    Medical Alumni Association Research Fellowship
  • 10/97-12/97
    Chief Resident, Department of Pathology, S.F. VA Medical Center
  • 4/98-6/98
    Chief Resident, Department of Pathology, S.F. General Hospital
  • 3/00-6/00
    Chief Resident, Department of Lab Medicine, S.F. General Hospital
  • 2002
    College of American Pathology Travel Award: Strategic Science Seminar Series, HER2/neu Testing of Breast Care Patients

Selected Publications

  1. Ding CC, Chan S, Mak J, Umetsu SE, Simko JP, Ruiz-Cordero R, Saunders T, Chan E. An exploration in pitfalls in interpreting SDHB immunohistochemistry. Histopathology. 2022 May 11.  View on PubMed
  2. Chan E, McKenney JK, Hawley S, Corrigan D, Auman H, Newcomb LF, Boyer HD, Carroll PR, Cooperberg MR, Klein E, Fazli L, Gleave ME, Hurtado-Coll A, Simko JP, Nelson PS, Thompson IM, Tretiakova MS, Troyer D, True LD, Vakar-Lopez F, Lin DW, Brooks JD, Feng Z, Nguyen JK. Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinoma. Mod Pathol. 2022 Feb 10.  View on PubMed
  3. Velarde N, Westphalen AC, Nguyen HG, Neuhaus J, Shinohara K, Simko JP, Larson PE, Magudia K. US lesion visibility predicts clinically significant upgrade of prostate cancer by systematic biopsy. Abdom Radiol (NY). 2022 03; 47(3):1133-1141.  View on PubMed
  4. Greenland NY, Cooperberg MR, Wong AC, Chan E, Carroll PR, Simko JP, Stohr BA. Molecular risk classifier score and biochemical recurrence risk are associated with cribriform pattern type in Gleason 3+4=7 prostate cancer. Investig Clin Urol. 2022 01; 63(1):27-33.  View on PubMed
  5. Chen CV, Croom NA, Simko JP, Stohr BA, Chan E. Differential immunohistochemical and molecular profiling of conventional and aggressive components of chromophobe renal cell carcinoma: pitfalls for diagnosis. Hum Pathol. 2022 01; 119:85-93.  View on PubMed
  6. Gibbons M, Starobinets O, Simko JP, Kurhanewicz J, Carroll PR, Noworolski SM. Identification of prostate cancer using multiparametric MR imaging characteristics of prostate tissues referenced to whole mount histopathology. Magn Reson Imaging. 2022 01; 85:251-261.  View on PubMed
  7. Chen E, Cario CL, Leong L, Lopez K, Márquez CP, Li PS, Oropeza E, Tenggara I, Cowan J, Simko JP, Kageyama R, Wells DK, Chan JM, Friedlander T, Aggarwal R, Paris PL, Feng F, Carroll PR, Witte JS. Cell-Free DNA Detection of Tumor Mutations in Heterogeneous, Localized Prostate Cancer Via Targeted, Multiregion Sequencing. JCO Precis Oncol. 2021; 5.  View on PubMed
  8. Greenberg SA, Washington SL, Lonergan PE, Cowan JE, Baskin AS, Nguyen HG, Odisho AY, Simko JP, Carroll PR. Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum Prostate Specific Antigen. J Urol. 2021 09; 206(3):706-714.  View on PubMed
  9. Feng FY, Huang HC, Spratt DE, Zhao SG, Sandler HM, Simko JP, Davicioni E, Nguyen PL, Pollack A, Efstathiou JA, Dicker AP, Todorovic T, Margrave J, Liu YS, Dabbas B, Thompson DJS, Das R, Dignam JJ, Sweeney C, Attard G, Bahary JP, Lukka HR, Hall WA, Pisansky TM, Shah AB, Pugh SL, Shipley WU, Tran PT. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. JAMA Oncol. 2021 04 01; 7(4):544-552.  View on PubMed
  10. Chen E, Cario CL, Leong L, Lopez K, Márquez CP, Chu C, Li PS, Oropeza E, Tenggara I, Cowan J, Simko JP, Chan JM, Friedlander T, Wyatt AW, Aggarwal R, Paris PL, Carroll PR, Feng F, Witte JS. Cell-free DNA concentration and fragment size as a biomarker for prostate cancer. Sci Rep. 2021 03 03; 11(1):5040.  View on PubMed
  11. Mekonnen ZK, Ashraf DC, Jankowski T, Grob SR, Vagefi MR, Kersten RC, Simko JP, Winn BJ. Acute Invasive Rhino-Orbital Mucormycosis in a Patient With COVID-19-Associated Acute Respiratory Distress Syndrome. Ophthalmic Plast Reconstr Surg. 2021 Mar-Apr 01; 37(2):e40-e80.  View on PubMed
  12. Cooperberg MR, Cowan JE, Lindquist KJ, Kobayashi Y, Simko JP, Bengtsson H, Singh K, Ngo V, Avila A, Newcomb LF, Tretriakova M, Lin DW, Stone S, Carroll PR, Paris PL. Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes. Eur Urol. 2021 01; 79(1):141-149.  View on PubMed
  13. Greenland NY, Cowan JE, Chan E, Carroll PR, Stohr BA, Simko JP. Prostate biopsy histopathologic features correlate with a commercial gene expression assay's reclassification of patient NCCN risk category. Prostate. 2020 12; 80(16):1421-1428.  View on PubMed
  14. Cario CL, Chen E, Leong L, Emami NC, Lopez K, Tenggara I, Simko JP, Friedlander TW, Li PS, Paris PL, Carroll PR, Witte JS. A machine learning approach to optimizing cell-free DNA sequencing panels: with an application to prostate cancer. BMC Cancer. 2020 Aug 28; 20(1):820.  View on PubMed
  15. van Leenders GJLH, van der Kwast TH, Grignon DJ, Evans AJ, Kristiansen G, Kweldam CF, Litjens G, McKenney JK, Melamed J, Mottet N, Paner GP, Samaratunga H, Schoots IG, Simko JP, Tsuzuki T, Varma M, Warren AY, Wheeler TM, Williamson SR, Iczkowski KA, ISUP Grading Workshop Panel Members. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am J Surg Pathol. 2020 08; 44(8):e87-e99.  View on PubMed
  16. Greenland NY, Cowan JE, Zhang L, Carroll PR, Chan E, Stohr BA, Simko JP. Expansile cribriform Gleason pattern 4 has histopathologic and molecular features of aggressiveness and greater risk of biochemical failure compared to glomerulation Gleason pattern 4. Prostate. 2020 05; 80(8):653-659.  View on PubMed
  17. Belkora J, Chan JM, Cooperberg MR, Neuhaus J, Stupar L, Weinberg T, Broering JM, Tenggara I, Cowan JE, Rosenfeld S, Kenfield SA, Van Blarigan EL, Simko JP, Witte J, Carroll PR. Development and pilot evaluation of a personalized decision support intervention for low risk prostate cancer patients. Cancer Med. 2020 01; 9(1):125-132.  View on PubMed
  18. Kornberg Z, Cooperberg MR, Cowan JE, Chan JM, Shinohara K, Simko JP, Tenggara I, Carroll PR. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance. J Urol. 2019 10; 202(4):702-709.  View on PubMed
  19. Friedlander TW, Welty C, Anantharaman A, Schonhoft JD, Jendrisak A, Lee J, Li P, Hough J, Stromlund A, Edwards M, Sangar S, Kobayashi Y, Simko J, Farrokhian N, Lindquist K, Greene S, Ontiveros P, Graf R, Rodriquez A, Suraneni M, Wang Y, Landers M, Carroll P, Cooperberg MR, Dittamore R, Paris PL. Identification and Characterization of Circulating Tumor Cells in Men Who have Undergone Prostatectomy for Clinically Localized, High Risk Prostate Cancer. J Urol. 2019 10; 202(4):732-741.  View on PubMed
  20. Herlemann A, Huang HC, Alam R, Tosoian JJ, Kim HL, Klein EA, Simko JP, Chan JM, Lane BR, Davis JW, Davicioni E, Feng FY, McCue P, Kim H, Den RB, Bismar TA, Carroll PR, Cooperberg MR. Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. Prostate Cancer Prostatic Dis. 2020 03; 23(1):136-143.  View on PubMed

Go to UCSF Profiles, powered by CTSI